Search - tctmd.com

Displaying 1 - 20 of 57

Sort: Relevancy | Date

Presentation TCT 2016

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Hitinder S. Gurm

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Presentation TVT 2016

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Presenter: David J. Cohen

June 16, 2016

Presentation Fellows 2016

Antithrombin Pharmacology for the Interventionalist

Presenter: Jeffrey W. Moses, David J. Cohen

April 16, 2016

Presentation Fellows 2016

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: Gary S. Mintz, David J. Cohen

April 16, 2016

Presentation TCT 2015

Complex Transradial Primary PCI: Case Examples of Problem Solving

Presenter: David E. Kandzari, Yves R. Louvard, Mauricio G. Cohen

October 15, 2015

Presentation TCT 2015

The Conundrum of Cost-effective but Unaffordable Care: The Plight of High-Tech New Interventional Therapies

Presenter: Aaron V. Kaplan, David J. Cohen

October 13, 2015

Presentation TCT 2015

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

Presenter: Nick Curzen, Ajay J. Kirtane, David J. Cohen

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Roxana Mehran

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All?

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Presenter: Stuart J. Pocock, Jan Tijssen, David J. Cohen

October 11, 2015

Presentation TVT 2015

Putting It All Together: What Are the Cost Implications?

Presenter: Sandra Lauck, David A. Wood, David J. Cohen

June 06, 2015

Presentation TVT 2015

Thoughtful Commentary: AS With Extreme Comorbidities (the Futile Patient)

Presenter: Howard C. Herrmann, Alec S. Vahanian, David J. Cohen

June 04, 2015

Advertisement

Opening Salvo: I Don't Believe That Door-to-Balloon Time Is a Critical Metric for Primary PCI In 2016!

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Antithrombin Pharmacology for the Interventionalist

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Complex Transradial Primary PCI: Case Examples of Problem Solving

The Conundrum of Cost-effective but Unaffordable Care: The Plight of High-Tech New Interventional Therapies

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

DAPT Duration After DES: Does 1 Size Fit All?

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Putting It All Together: What Are the Cost Implications?

Thoughtful Commentary: AS With Extreme Comorbidities (the Futile Patient)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content